Preview

Опухоли женской репродуктивной системы

Расширенный поиск

СОВРЕМЕННЫЕ АСПЕКТЫ ЦИТОЛОГИЧЕСКОГО СКРИНИНГА РАКА ШЕЙКИ МАТКИ: ОБЗОР

https://doi.org/10.17650/1994-4098-2009-0-3-4-78-83

Полный текст:

Аннотация

Ежегодно в мире регистрируется более 500 000 случаев заболевания раком шейки матки среди женщин. При этом почти половина боль- ных умирает в течение первого года в связи с поздней диагностикой заболевания. В связи с этим проблема ранней диагностики рака на се- годняшний день встает особенно остро.

Об авторе

Л. Е. Комарова
ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. Ferlay J., Bray F., Pisani P. et al. Globocan 2002: Cancer incidence, mor- tality and prevalence. Worldwide. IARC Cancer Base No5. Version 2.0. Lyon, France: IARC Press, 2004.

2. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year. The global picture. Eur J Cancer 2000;37(8):4—66.

3. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ РАМН им. Н.Н. Блохина 2008;2(19):прил 1.

4. Злокачественные новообразования в России в 2002 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2004.

5. Ferlay J., Bray F., Pisani P. et al. Globocan 2000: Cancer incidence, mor- tality and prevalence worldwide, IARC Cancer Base No 5, Version 1.0. Lyon, France: IARC press, 2001.

6. UK National office of Statistics: http//www.statistics.gov uk / Stat base/is data set. asp ? vink =9096-last accessed on 01.05.06

7. US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Mortality. Atlanta (GA): department of Health and Human Services, Centers Control and Prevention, and National Cancer Institute, 2007.

8. Wang S.S., Sherman M.E., Hildesheim A. et al. Cervical adenocarci- noma and squamous cell carcinoma inci- dence trends among white women and black women in the United States for 1976—2000. Cancer 2004;100(5):1035—44.

9. Sherman N.E., Wang S.S., Carreon J. et al. Mortality trends for cervical squa- mous and adenocarcinoma in the United States. Relation to incidence and sur- vival. Cancer 2005;103(6):1258—64.

10. Kyndi M., Frederiksen K., Kruger K. Cervical cancer incidence in Denmark over six decades (1943—2002). Acta Obstet Gynecol Scand 2006;85(1):106—11.

11. National Cancer Institute United States Cancer Statistic: 2002 Incidence and Mortality.

12. Munoz N. Human papillomavirus and cancer: the epidemiological evi- dence. J Clin Virol 2000:19:1—5.

13. Walboomers J.M.M., Jacobs M.V., Manos M.M. et al. Human papilo- mavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12—9.

14. Kapeu A.S., Luostarinen T., Jellum E. et al. Is smoking an independent risk fac- tor for invasive cervical cancer? A Nested Case-Control Study within Nordic Biobanks.

15. Castlehttp P.E.://www.imaginis. Com/cervical-cancer/news/ news2.09.03.asp

16. Roteli-Martins C.M., Panetta K., Alves V.A. et al. Cigarette smoking and high-risk HPV DNA as predisposing fac- tors for high-grade cervical intraepithelial neoplasia (CIN) in young Brazilian women. Act Obstet Gynecol Scandinav 1998;77(6):678.

17. Coker A.L., Bond S.M., Williams A. et al. Active and passive smoking, high- risk human papillomaviruses and cervical neoplasia. Cancer Detect Prev 2002;26(2):121—8.

18. Wieland U., Pfister H. Papillomavirus in human pathology. Epidemiology, pathogenesis and onco- genic role. In Human Papilloma Virus: A clinical atlas. Gross , Barrasso eds. Ulstein Mosby, 1997. p. 1—18.

19. Monsonego J. Prevention of cervical cancer (II): Prophylactic HPV vaccina- tion, current knowledge, practical proce- dures and new issues. Press Med 2007;36(7—8):1150—1.

20. WHO. Press Release, 1996; 47.

21. Baay M.F., Verhoeven V., Avonts D. et al. Risk factors for cervical cancer development: what do women think? Sex Health 2004;1:145—9.

22. Castle P. Cervical cancer: epidemiol- ogy and prevention. NCI summer cur- riculum in cancer prevention. July 2 through 27, 2007 Module 4-Screening and Early Detection.

23. Аксель Е.М., Двойрин В.В., Трапезников Н.Н. Заболеваемость и смертность от злокачественных новообразований населения России и стран СНГ в 1992 г. М., 1994.

24. Pettersson F., Naslund I., Walker B. Evaluation of the effect of papanicolaou screening in Sweden: record linkage between a central screening registry and the national cancer registry. Screening for cancer of the uterine cervix. IARC Scient Public 1986;(76):91—105.

25. Macgregor J.E., Moss S., Parkin D.M. et al. Cervical cancer screening in North- East Scotland. Screening for cancer of the uterine cervix. IARC Scient Publicat 1986;(76):25—36.

26. Quinn M., Babb P., Jone J. et al. Effect of screening on incidence and mortality from cancer of cervix in England: Evaluation based on routinely collected statistics. BMJ 1999;318:904—8.

27. Mc Croy D.C., Matchar D.B., Bastian L. et al. Evaluation of cervical cytology, evidence report (technology assessment No5) Prepared by Duke University Contract No.290-97-0014 AHCPR Publications No.299-EO101, 1999.

28. Renshaw A.A., Mody D.R., Lozaro R.L. et al. Detection of adeno- carcinoma in situ of the cervix in Papanicolaou tests. Arch Pathol Lab Med 2004;128:153—7.

29. Bray F., Carstensen B., Moller H. et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarc Prev 2005;14:2191—9.

30. Zur Hausen H. Papillomavirus and cancer from basic studies to clinical appli- cation. Nat Rev Cancer 2(5):342—50.

31. Richardson H., Pintos J., Franco E. et al. Determinants of low-risk and high- risk cervical human papillomavirus infec- tions in Montreal University students. Sex Transm Dis 2000;27:79—86.

32. Молчанов Д. Вирус папилломы человека и рак шейки матки: уникальная взаимосвязь и вызов современной медицине. Здор Укр 2007;(1):3.

33. Баджиева Б.А. Генетическая нестабильность и аллельный полиморфизм у больных с дисплазиями и раком шейки матки, вызванными персистенцией ДНК вируса папилломы человека. Автореф. дис. ... канд. мед. наук. М., 2008.

34. Мазуренко Н.Н. Роль вирусов папиллом в канцерогенезе рака шейки матки. Совр онкол 2003;5(1):7—10.

35. Киселев Ф.Л. Вирус-ассоциированные опухоли человека: рак шейки матки и вирусы папиллом. Биохимия 2000;65:79—91.

36. Ponten J., Adami H.O., Bergstrom R. et al. Strategies for global control of cervi- cal cancer. Int J Cancer 1995;60(1):1—26.

37. Минкина О. Цитология против рака. 9 мес 2005;(8).

38. Judson P.L, Habermann E.B., Baxter N.N. et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006;107:1018—22.

39. Sexually transmitted infections quar- terly report. Anogenital warts and HPV infection in England and Wales. CDR week 2001;11(35).

40. Source: Health Protection Agency: http//www.hpa.org.uk/infections/ topics a_z/hiv_and sti/epidemiology/sisludest 05.htm

41. Cox J.T. Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus. Baillieres Clin Obstet Gynaecol 1995;9(1):1—37.

42. Olsson S.E., Villa L., Costa R. et al. Induction of immune memory following administration of a prophylactic quadri- valent human papillomavirus (HPV) types 5/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931—9.

43. Gardasil. Summary of Product char- acteristics. Human papillomavirus & related genital diseases. Questions & Answers, 2007. p. 57.

44. Garland S.M., Wheeler C.M., Peterz G. et al. Quadrivalent vaccine against Human Papillomavirus to prevent anogenital diseases. N Engl Med 2007;1928—43.

45. Myers E.R., McGrory D.C., Subramanian S. et al. Setting the target for a better cervical screening test: char- acteristics of a cost-effective test for cer- vical neoplasia screening. Obstet Gynecol 2000;96(5 Pt 1):645—52.

46. Nanda K., Mc Grory D.C., Myers E.R. et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormal- ities: a systemic review. Ann Intern Med 2000;132(10):810—9.

47. Kotaniemi-Talonen L., Anttila A., Malila N. et al. Screening with primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;Jan 7 (Epub ahead of print)

48. Kulasingam S.L., Hughes J.P., Kiviat N.B. et al. Evaluation if human papillomavirus in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288 (14):1749—57.

49. Lörincz A.T. Screening for cervical cancer: new alternatives and research. Salud Pulica Mex 2003;45(Suppl 3):5376—87.

50. Naucler P., Ryd W., Tornberg S. et al. Efficacy of HPV DNA testig with cytol- ogy triage and/or repeat HPVDNA test- ing in primary cervical cancer screening. J Natl Cancer Inst 2009;101(2):88—99.

51. Syrjänen K. New Concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur J Gynaecol Oncol 2008;29(3): 205—21.


Для цитирования:


Комарова Л.Е. СОВРЕМЕННЫЕ АСПЕКТЫ ЦИТОЛОГИЧЕСКОГО СКРИНИНГА РАКА ШЕЙКИ МАТКИ: ОБЗОР. Опухоли женской репродуктивной системы. 2009;(3-4):78-83. https://doi.org/10.17650/1994-4098-2009-0-3-4-78-83

For citation:


Komarova L.E. CURRENT ASPECTS OF CYTOLOGICAL SCREENING FOR CANCER OF THE CERVIX UTERI: A REVIEW. Tumors of female reproductive system. 2009;(3-4):78-83. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-3-4-78-83

Просмотров: 311


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)